Iron deficiency in parkinsonism: Region-specific iron dysregulation in parkinson's disease and multiple system atrophy

Journal of Parkinson's Disease

Volumn 3, Issue 4, 2013, Pages 523-537

  Visanji, Naomi P ^a   Collingwood, Joanna F ^b   Finnegan, Mary E ^b   Tandon, Anurag ^c   House, Emily ^d   Hazrati, Lili Naz ^c  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d KEELE UNIVERSITY   (United Kingdom)

Author keywords

Ferritin; Ferroportin; Inflammation; Iron; Multiple system atrophy; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; FERRITIN; FERROPORTIN; IRON;

ADULT; AGED; ANEMIA; ARTICLE; BIOACCUMULATION; BIOAVAILABILITY; CELL TYPE; CHRONIC DISEASE; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN TISSUE; IRON DEFICIENCY; IRON TRANSPORT; MALE; MICROGLIA; NERVE DEGENERATION; PARKINSON DISEASE; PARKINSONISM; PONS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA; TISSUE LEVEL;

FERRITIN; FERROPORTIN; INFLAMMATION; IRON; MULTIPLE SYSTEM ATROPHY; PARKINSON'S DISEASE;

AGED; BRAIN; BRAIN CHEMISTRY; CASE-CONTROL STUDIES; CATION TRANSPORT PROTEINS; FEMALE; FERRITINS; HUMANS; IRON; MAGNETOMETRY; MALE; MICROGLIA; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; SPECTROPHOTOMETRY, ATOMIC;

EID: 84898763271     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-130197     Document Type: Article

References (40)

1. Forno LS (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol, 55, 259-272.
2. Crichton R & Ward RJ (2008) Metal-based neurodegeneration -from molecular mechanisms to therapeutic strategies in Parkinson's disease. John Wiley & Sons Ltd, 2006.
3. Davies P, Moualla D & Brown DR (2011) Alpha-synuclein is a cellular ferrireductase. PLoS One, 6, e15814.
4. Ayton S, Lei P, Bush AI & Finkelstein DI (2013) Alpha synuclein is a major regulator of iron homeostasis, in 11th Annual Conference on Alzheimer's and Parkinson's diseases (AD/PD). Florence, 2013.
5. Riederer P, Dirr A, Goetz M, Sofic E, Jellinger K & Youdim MB (1992) Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann Neurol, 32 (Suppl) S101-s104.
6. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR & Daniel SE, et al. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain, 114(Pt 4), 1953-1975.
7. Dexter DT, Jenner P, Schapira AH & Marsden CD (1992) Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol, 32(Suppl), S94-S100.
8. Friedman A, Arosio P, Finazzi D, Koziorowski D & Galazka-Friedman J (2011) Ferritin as an important player in neurodegeneration. Parkinsonism Relat Disord, 17, 423-430.
9. Arosio P & Levi S (2010) Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim Biophys Acta, 1800, 783-792.
10. Bolzoni F, Giraudo S, Lopiano L, Bergamasco B, Fasano M & Crippa PR (2002) Magnetic investigations of human mesencephalic neuromelanin. Biochim Biophys Acta, 1586, 210-218.
11. Hautot D, PankhurstQA&Dobson J (2005) Superconducting quantum interference device measurements of dilute magnetic materials in biological samples. Rev Sci Instrum, 76.
12. Collingwood JF, Chong RK, Kasama T, Cervera-Gontard L, Dunin-Borkowski RE & Perry G, et al. (2008) Threedimensional tomographic imaging and characterization of iron compounds within Alzheimer's plaque core material. J Alzheimers Dis, 14, 235-245.
13. Hautot D, PankhurstQA&Dobson J (2005) Superconducting quantum interference device measurements of dilute magnetic materials in biological samples. Rev Sci Instrum, 76.
14. House E, Esiri M, Forster G, Ince PG & Exley C (2012) Aluminium, iron and copper in human brain tissues donated to the Medical Research Council's Cognitive Function and Ageing Study. Metallomics, 4, 56-65.
15. Zecca L, Gallorini M, SchunemannV, Trautwein AX, Gerlach M & Riederer P, et al. (2001) Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: Consequences for iron storage and neurodegenerative processes. J Neurochem, 76, 1766-1773.
16. Crichton RR, Dexter DT & Ward RJ (2011) Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm, 118, 301-314.
17. Friedman A, Galazka-Friedman J & Koziorowski D (2009) Iron as a cause of Parkinson disease -a myth or a well established hypothesis? Parkinsonism Relat Disord, 15(Suppl 3), S212-S214.
18. Earle KM (1968) Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. J Neuropathol Exp Neurol, 27, 1-14.
19. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP & Hebenstreit G, et al. (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm, 74, 199-205.
20. Griffiths PD & Crossman AR (1993) Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia, 4, 61-65.
21. Oakley AE, Collingwood JF, Dobson J, Love G, Perrott HR& Edwardson JA, et al. (2007) Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology, 68, 1820-1825.
22. De Volder AG, Francart J, Laterre C, Dooms G, Bol A & Michel C et al. (1989) Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol, 26, 239-247.
23. Mash DC, Pablo J, Buck BE, Sanchez-Ramos J & Weiner WJ (1991) Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice. Exp Neurol, 114, 73-81.
24. Block ML, Zecca L & Hong JS (2007) Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat Rev Neurosci, 8, 57-69.
25. McGeer PL, Itagaki S, Boyes BE&McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 38, 1285-1291.
26. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA & Karluk D (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol, 46, 598-605.
27. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M &HashizumeY(2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol, 106, 518-526.
28. Moos T, Rosengren Nielsen T, Skjorringe T & Morgan EH (2007) Iron trafficking inside the brain. J Neurochem, 103, 1730-1740.
29. Persichini T, De Francesco G, Capone C, Cutone A, di Patti MC & Colasanti M, et al. (2012) Reactive oxygen species are involved in ferroportin degradation induced by ceruloplasmin mutant Arg701Trp. Neurochem Int, 60, 360-364.
30. Moos T & Rosengren Nielsen T (2006) Ferroportin in the postnatal rat brain: Implications for axonal transport and neuronal export of iron. Semin Pediatr Neurol, 13, 149-157.
31. De Domenico I,Ward DM, Langelier C,Vaughn MB, Nemeth E & Sundquist WI, et al. (2007) The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell, 18, 2569-2578.
32. Rouault TA (2001) Systemic iron metabolism: A review and implications for brain iron metabolism. Pediatr Neurol, 25, 130-137.
33. Kono S, Yoshida K, Tomosugi N, Terada T, Hamaya Y & Kanaoka S, et al. (2010) Biological effects of mutant ceruloplasmin on hepcidin-mediated internalization of ferroportin. Biochim Biophys Acta, 1802, 968-975.
34. Yomono H, Kurisaki H, Murayama S, Hebisawa A, Miyajima H & Takahashi Y (2003) An autopsy case of multiple system atrophy with a heteroallelic ceruloplasmin gene mutation. Rinsho Shinkeigaku, 43, 398-402.
35. Kurisaki H, Yomono H, Murayama S & Hebisawa A (2002) Multiple system atrophy with a-/hypo-ceruloplasminemia: Distribution of iron in brains of 2 autopsy cases. Rinsho Shinkeigaku, 42, 293-298.
36. Cairo G, Tacchini L & Pietrangelo A (1998) Lack of coordinate control of ferritin and transferrin receptor expression during rat liver regeneration. Hepatology, 28, 173-178.
37. Zechel S, Huber-Wittmer K & von Bohlen und Halbach O (2006) Distribution of the iron-regulating protein hepcidin in the murine central nervous system. J Neurosci Res, 84, 790-800.
38. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A & Ward DM, et al. (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 306, 2090-2093.
39. Weiss G&Goodnough LT (2005) Anemia of chronic disease. N Engl J Med, 352, 1011-1023.
40. Ishizawa K, Komori T, Sasaki S, Arai N, Mizutani T&Hirose T (2004) Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol, 63, 43-52.